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2008). Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs) are a
new class of anti-arthritic drugs, which inhibit in a balanced way both
COX-1 and COX-2 while releasing nitric oxide, an important modulator of
vascular tone. We present here the effects of HCT 1026, a ﬂurbiprofen-
based CINOD, on chondrocytes, focusing on their catabolic and anabolic
activities, as well as activation of inﬂammatory pathways.
Methods: Isolated primary cultures of bovine and human articular chon-
drocytes (BAC and HAC) were preincubated with 10mM HCT 1026 or
ﬂurbiprofen and stimulated with Il-1b, in hypoxic or normoxic conditions.
Levels of mRNA for extracellular matrix proteins (aggrecan and collagen
type II) and matrix metalloproteases (MMPs), as well as TGFb receptor,
were determined by quantitative RT-PCR. NO release was assessed
on cell supernatants through the Griess reaction, and activities of NF-
úB and AP-1 were determined by electrophoretic mobility shift assay.
NO donation from HCT 1026 was evaluated by testing its vasorelaxing
activity in norepinephrine-precontracted rabbit aortic rings, in presence
or absence of 10 mM ODQ (a speciﬁc inhibitor of NO-dependent cGMP
formation).
Results: In hypoxic human articular chondrocytes stimulated with Il-1b,
both HCT 1026 and ﬂurbiprofen decreased expression of MMP-1 and -3
and TGF-b receptor by 20 to 40%. However, only HCT 1026 inhibited
Il-1b-dependent NO overproduction while did not affect basal aggrecan
or type II collagen mRNAs. Moreover, in BAC cultured in normoxic
conditions, HCT 1026 inhibited NF-úB and AP-1 activation, whereas
ﬂurbirprofen affected only AP-1 activity. HCT 1026, but not ﬂurbiprofen,
induced aorta vasorelaxation, with an EC50 of 5.9±1.2mM. ODQ pretreat-
ment abolished this effect, conﬁrming that vascular relaxation by HCT
1026 was based on its NO donating properties.
Conclusions: The CINOD HCT 1026 modulates chondrocytes catabolic
and anabolic metabolism, causing reduction of inﬂammatory markers
such as NO biosynthesis and activation of NF-úB. Moreover, HCT 1026
is able to donate biologically relevant nitric oxide, which can modulate
vascular tone. If conﬁrmed in in vivo studies, our data may provide
evidence that the ability of CINODs to donate NO have a potential
beneﬁcial impact on joint cartilage in OA patients.
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Purpose: The research was aimed at evaluating of the effectiveness
of meloxicam (revmoxicam) for treatment of pain syndrome under knee
osteoarthritis, low back pain and neck pain in elderly people.
Methods: The patients were devided into three groups. The ﬁrst group
included 11 patients (aged 61.1±5.54 years) with neck pain, the second
group included 10 patients (aged 59.4±4.65 years) with low back pain and
the third group included 10 patients (aged 57.9±7.5 years) with knee os-
teoarthritis. All patients took meloxicam 15mg once per day during 5 days.
The following methods of study were used: Mc-Gill questionnaire, VAS,
WOMAC, determination of life quality by Roland-Morris questionnaire,
Neck disability index, EuroQol 5D scale.
Table 1. Dynamics of pain syndrome intensive after meloxicam treatment in patient of different
groups.
Index Group Before
treatment
After 5 days
of treatment
P Two weeks without
treatment
P
Index of pain, cm I 444±0.71 4.11±0.78 0.35 3.22±3.00 0.01
II 5.13±0.59 4.13±0.79 0.03 3.63±0.52 0.003
III 5.98±2.22 3.56±1.74 0.001 3.66±1.86 0.043
Descriptors, ball I 9.56±2.23 7.56±2.40 0.09 7.56±1.71 0.12
II 11.0±2.29 8.63±2.79 0.016 9.63±3.65 0.49
III 10.60±4.70 7.40±4.80 0.008 8.70±6.00 0.043
Ranks, ball I 18.78±5.17 13.22±5.28 0.07 12.00±3.52 0.03
II 23.50±6.71 16.88±6.61 0.006 18.88±8.06 0.36
III 23.30±16.10 16.50±11.70 0.01 18.50±15.0 0.57
Results: After 5 days of treatment patients, who was taking meloxicam,
noticed a signiﬁcant decrease of pain syndrome and it became low after
two weeks without treatment [Table].
Signiﬁcant decrease of all parameters of pain syndrome in second and
third groups was observed after 5 days. Intensity of pain syndrome was
also certainly decreased after two weeks without treatment in all groups
by some parameters. The difference of effectiveness of meloxicam in
patient with different diseases was observed by VAS: decrease of pain
syndrome in the ﬁrst group was – 7%, in the second groups – 17%,
and in the third group – 39%, F=2.76, p = 0.08. During the period of
research no patients who undergone treatment had registered any side
effects. There was no signiﬁcant difference between groups dealing with
the improvement of patient’s everyday activity.
Conclusions: It can be concluded that the meloxicam is effective and
safe in the treatment of low back pain syndrome, neck pain syndrome
and pain syndrome under knee osteoarthritis in elderly people. However,
the best effect of meloxicam was observed in patients with pain syndrome
under knee osteoarthritis that can be explained by the inﬂammatory
component of osteoarthritis pathogenesis.
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Purpose: The research was aimed at evaluating the effectiveness of two
regimes (continuous and interrupted) of Theraﬂex (500mg glucosamine
hydrochloride, 400mg chondroitin sulphate) in patients with knee os-
teoarthritis. Outcomes evaluated were pain, measures of performance
(function, activity of daily living, disability), employment status, range of
motion, and patient satisfaction/patient global perceived effects.
Methods: The ﬁrst group included 50 patients (aged 64.5±1.1 years)
with knee osteoarthritis (II stage, Kellgren-Lawrence’s classiﬁcation), who
took the drug in continuous regime during 9 months. The second group
included 50 patients with the same diagnosis (aged 64.6±1.0 years),
who took Theraﬂex twice during 3 months with 3 months interruption.
We examined the patients before the treatment and after 1, 3, 6, 9 and
12 months. Methods of study: Mc-Gill questionnaire, visual-analogical
scale (VAS), Lequen’s index, WOMAC, EuroQol-5D, 15-m. test, 6-min.
test.
Results: After three months of Theraﬂex’s treatment it was observed a
reliable decrease of pain syndrome in both groups by WOMAC, decrease
of constraint in movements, improvement of index of everyday activity,
VAS, 15-m.test. Examination of patients during 6, 9 and 12 months
show the effectiveness of both regimes of the therapy. Intensity of pain
syndrome and functional activity didn’t differ between the groups.
Conclusions: During 1-year period two regimes of Theraﬂex it was
established effective decrease of intensity of the pain syndrome and
improvement of everyday activity in patients with knee osteoarthritis. The
analgesic effect after taking Theraﬂex becomes noticeable after three
months and quality of life signiﬁcantly improved in patients of both groups.
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Purpose: The FLEXX trial studied the 6 month efﬁcacy and safety of a
non-avian form of IA hyaluronan for OA of the knee.
Methods: This was a randomized, saline-controlled, double-blind study
of 586 patients with primary OA of the knee were evaluated prior to and
following 3 weekly IA injections of hyaluronan or buffered saline. The
primary efﬁcacy measurement was pain recorded for the signal knee
after a 50-foot walk. Secondary variables included the 3 subscales of the
WOMAC, OARSI responder criteria, patient global assessment, use of
rescue medication, quality of life (SF-36), and safety.
Results: The ITT population included Hyaluronan n=291 and Saline
n = 295. There were 12% dropouts (Hyaluronan n=34; Saline n = 34).
Hyaluronan demographics: Age 62.5±10.6 (SD), women 63%, BMI 32±7,
Kellgren-Lawrence grade 2−41%, grade 3−59%, initial pain 56±22 with
minimal differences from the saline group. After 26 weeks, there was a
signiﬁcant improvement in pain recorded after a 50-foot walk (ANCOVA;
p = 0.028). Secondary variables were generally supportive of the primary
measurement. Serious adverse events occurred in Hyaluronan (n = 10)
and Saline (n = 9) groups. Arthralgia occurred in Hyaluronan (n = 27)
and Saline (n = 35) groups. Local injection site reactions occurred in
Hyaluronan (n = 2) and Saline (n = 1) groups.
Conclusions: IA hyaluronan was signiﬁcantly superior to saline for OA
of the knee over a 6-month period despite a large beneﬁcial effect of IA
saline.
